Has Baxter International Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Baxter International (NYS: BAX) fits the bill.

The quest for perfectionStocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.

Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that a company can turn revenue into profit.

Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.

Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.

Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.

Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Baxter International.

Baxter has focused for years on various medical devices and pharmaceuticals targeting blood-related diseases, as well as drug delivery systems and dialysis treatment. That business has produced stable, though slow, growth over the years.

But late last year, Baxter jumped onto one of the biggest recent trends in the industry: partnerships to develop biosimilar drugs. In response to giant Amgen (NAS: AMGN) setting up a deal with Watson Pharmaceuticals and Teva Pharmaceuticals (NYS: TEVA) pairing with Swiss company Lonza, Baxter teamed up with Momenta Pharmaceuticals (NAS: MNTA) for biosimilar development. Just as generics have revolutionized the standard pharmaceutical compound business, biosimilars have the potential to make more-complicated biologic drugs cheaper and more readily available.

In addition, Baxter is joining in the race to fight Alzheimer's. With its Gammagard drug set to complete phase 3 trials next year, it could prove to be a blockbuster for Baxter, if successful.

Still, Baxter has had setbacks. Its partnership with Halozyme (NAS: HALO) got bad news when the FDA turned down its HyQ immunodeficiency disease drug. Although Halozyme got hit hard, Baxter's stock barely budged after the expected news in early August.

For Baxter to improve, its most likely path will be for biosimilar development to take off. Success there could help reawaken growth, and send Baxter closer to perfection in the years to come.

Keep searchingNo stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess, and learning how to separate out the best investments from the rest.

Check out our free report: These Could Skyrocket After the 2012 Presidential Election. Barack Obama and Mitt Romney have competing visions for getting America back on track, but The Motley Fool will have you prepared to profit -- no matter who wins! Download your copy now, for free, and discover hidden ways to profit from the election.

Click here to add Baxter International to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.